WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 2, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy , President and CEO, will present at the upcoming 36 th Annual J.P.
Second ADC Using ImmunoGen’s Novel DNA-Alkylating Payloads to Enter the Clinic WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 4, 2018-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the first patient has
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 24, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the appointment of Stuart A. Arbuckle to its Board of Directors. Mr.
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 26, 2018-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m.
WALTHAM, Mass. --(BUSINESS WIRE)--Feb. 6, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
Significant Operational and Financial Progress in 2017 with a Robust Set of Data and Events Expected in 2018 Mirvetuximab Soravtansine Phase 3 FORWARD I Trial to Complete Enrollment by Mid-Year; FORWARD II Combination Data to be Presented Throughout 2018 Novel ADC Pipeline Continues to Advance with
WALTHAM, Mass. --(BUSINESS WIRE)--Mar. 14, 2018-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that three posters highlighting the Company’s expertise in ADCs will be presented at the upcoming
WALTHAM, Mass.--( BUSINESS WIRE )-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced encouraging efficacy and favorable tolerability data from the FORWARD II cohort assessing mirvetuximab soravtansine in
WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 20, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m.
WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 25, 2018-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Blaine McKee , Ph.D. has been appointed Executive Vice President and Chief Business Officer.